Substance / Medication

Cefdinir

Overview

Active Ingredient
cefdinir
RxNorm CUI
25037

Indications

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empir

Labeler: PD-Rx Pharmaceuticals, Inc.Updated: 2026-02-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Cefdinir capsules are contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

11 trials linked to this intervention

11
Total Trials
2
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial.
Murphy Tanya K, Parker-Athill E Carla, Lewin Adam B et al. · J Child Adolesc Psychopharmacol · 2015
PMID: 25299463RCTFull text (PMC)
Bioequivalence evaluation of cefdinir in healthy fasting subjects.
Chen J, Jiang B, Lou H et al. · Arzneimittelforschung · 2012
PMID: 22331756RCT
Cefdinir vs cephalexin for the treatment of urinary tract infections: A retrospective evaluation.
Lloyd Andie, Grey Jonathan, Fronczek Christopher et al. · Am J Health Syst Pharm · 2024
PMID: 38349523Observational
Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media.
Casey Janet R, Block Stan L, Hedrick Jim et al. · Drugs · 2012
PMID: 23039319ObservationalFull text (PMC)
Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study.
Khan Abbas, Iqbal Zafar, Khan Muhammad Imran et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2011
PMID: 21782531Observational
Comparative bioavailability of two cefdinir suspension formulations in Middle Eastern healthy volunteers after single oral administration.
Zaid Abdel Naser, Alhaique Franco, Kort Jamal et al. · Arzneimittelforschung · 2008
PMID: 18488813Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefdinir (substance)
SNOMED CT
108677001
UMLS CUI
C0060405
RxNorm CUI
25037
Labeler
PD-Rx Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 13 entities in the Healos knowledge graph.

13
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
11
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Cefdinir — Conditions, Biomarkers & Specialists | Healos | Ltrl